Getein Biotech (603387.SS) Earnings Analysis
Getein Biotech (603387.SS) has no confirmed upcoming earnings date. Trailing P/E 19.00.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603387.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 603387.SS. This page updates as the calendar is published.
603387.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-29 | 0.102 CNY | n/a | n/a | n/a |
| 2025-06-30 | 0.08996 CNY | n/a | n/a | n/a |
| 2025-04-29 | 0.13 CNY | n/a | n/a | n/a |
| 2024-12-31 | 0.09615 CNY | n/a | n/a | n/a |
603387.SS valuation and analyst view
| Trailing P/E | 19.00 |
|---|---|
| Trailing EPS | 0.45875 CNY |
| Price / book | 1.57 |
| Dividend yield | 2.73% |
| Market cap | 4.41B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Getein Biotech (603387.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 603387.SS. This page updates as the calendar is published.
Did 603387.SS beat earnings last quarter?
Consensus estimate data was not available for 603387.SS's 2025-09-29 report.
What is 603387.SS's current P/E ratio and EPS?
603387.SS trades at a trailing P/E of 19.00 on trailing EPS of 0.45875101956554115 CNY.
What do analysts rate 603387.SS?
603387.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.